Press Releases

Press Releases

Press Releases

May 10, 2018

Advisory Committee members vote 12-8 to support approval CAMBRIDGE, Mass. and CARLSBAD, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the U.S.

May 3, 2018

TTR licensing transaction positions Akcea for two rare disease drug launches in 2018 FDA extended TEGSEDI TM (inotersen) PDUFA date to October 6, 2018 $445 million in pro forma cash to fund the company through key milestones in 2019 Conference Call Webcast Thursday, May 3 , 4:30 p.m.

May 2, 2018

Program currently available in the U.S. and select countries in Europe; initiating additional countries throughout 2018 CAMBRIDGE, Mass. , May 02, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA) today announced it has expanded its global early access program (EAP) to the United

April 26, 2018

Results to be presented show significant reduction in triglyceride levels associated with reductions of pancreatitis and burden of disease in patients with FCS CAMBRIDGE, Mass. and LAS VEGAS , April 26, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.

April 26, 2018

Webcast scheduled for Thursday, May 3rd at 4:30 p.m. Eastern Time CAMBRIDGE, Mass. , April 26, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , announced today that it will host a live webcast on Thursday, May 3 rd at 4:30 p.m.

April 21, 2018

Two oral presentations further demonstrate inotersen’s impact on efficacy and safety and on patient quality of life CAMBRIDGE, Mass. , April 21, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.

April 17, 2018

  Akcea shareholders approved the transaction on April 16 at a Special Meeting of Stockholders                              Ionis licenses Akcea worldwide rights to inotersen and AKCEA-TTR-L Rx                CAMBRIDGE, Mass. and CARLSBAD, Calif., April 17, 2018 (GLOBE NEWSWIRE) --  Akcea

April 17, 2018

CAMBRIDGE, Mass. , April 17, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , today announced that, following today’s close of the transaction licensing Akcea the exclusive, worldwide rights to inotersen and AKCEA-TTR-L Rx , Sarah Boyce

March 26, 2018

- Advocates Designate First Friday in November as FCS Awareness Day - CAMBRIDGE, Mass. , March 26, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat people with serious and rare

March 26, 2018
Continued benefit with long-term inotersen treatment observed in both quality of life (Norfolk-QOL-DN) and neuropathy (mNIS+7) measures in hATTR amyloidosis patients; Cardiac benefit with inotersen treatment observed in a Phase 2 study in patients with wild-type and hereditary ATTR cardiomyopathy